Loading...

뉴스 목록

VISEN Pharmaceutical's TransCon C-type natriuretic peptide Phase II clinical trial application approved in China

2021-02-08


January 7, VISEN Pharmaceuticals announced that it had submitted TransCon CNP (TransCon C-type natriuretic peptide) for injection to the National Medical Products Administration (NMPA) for the treatment of achondroplasia (ACH) patients. Phase II new drug clinical trial application has been approved. The ACcomplisH China clinical trial is about to be launched in China, achieving global synchronization with ACcomplisH (a TransCon C-type natriuretic peptide phase II global clinical trial being carried out by Ascendis Pharma).


TransCon CNP inhibits the over-activated fibroblast growth factor receptor 3 (FGFR3) signaling pathway by continuously providing active CNP. Slowly released once a week to help children with ACH rebuild the balance of bone growth, while improving and preventing the complications of ACH. TransCon CNP has obtained orphan drug designation from the US Food and Drug Administration and the European Commission.


당사는 귀하의 웹사이트 이용을 더 잘 이해하기 위해 쿠키를 사용하고자 하며, 이는 향후 웹사이트 방문 시 귀하의 경험을 개선하는 데 도움이 될 것입니다. 브라우저 설정에서 이 설정을 변경할 수 있습니다. 쿠키 사용에 대한 자세한 내용은 개인정보 보호정책을 참조하세요.